Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 7.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 192,293 shares of the biotechnology company’s stock after selling 14,705 shares during the period. Mutual of America Capital Management LLC’s holdings in Exelixis were worth $4,613,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of EXEL. Contravisory Investment Management Inc. purchased a new stake in shares of Exelixis in the 4th quarter valued at about $26,000. Denali Advisors LLC lifted its holdings in shares of Exelixis by 7,995.2% in the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,679 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Exelixis by 245.6% in the 1st quarter. Covestor Ltd now owns 1,676 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,191 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Exelixis by 44.2% in the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 604 shares during the last quarter. Finally, Ronald Blue Trust Inc. lifted its holdings in shares of Exelixis by 87.2% in the 3rd quarter. Ronald Blue Trust Inc. now owns 2,552 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,189 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 47,020 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares in the company, valued at approximately $8,255,375.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director David Edward Johnson purchased 190,000 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were acquired at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now directly owns 1,100,730 shares in the company, valued at approximately $22,785,111. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 47,020 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $21.45, for a total value of $1,008,579.00. Following the completion of the sale, the executive vice president now owns 384,866 shares in the company, valued at approximately $8,255,375.70. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

Exelixis Trading Down 0.5 %

NASDAQ EXEL opened at $22.70 on Tuesday. The business’s 50 day moving average is $22.33 and its two-hundred day moving average is $22.11. Exelixis, Inc. has a 12-month low of $18.08 and a 12-month high of $24.34. The stock has a market capitalization of $6.88 billion, a price-to-earnings ratio of 35.47, a PEG ratio of 0.60 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. The company had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. Equities analysts forecast that Exelixis, Inc. will post 1.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on EXEL. BTIG Research assumed coverage on Exelixis in a report on Tuesday, December 19th. They issued a “buy” rating and a $27.00 target price for the company. Stifel Nicolaus upped their price objective on Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. Barclays downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective for the company. in a research note on Thursday, April 11th. Royal Bank of Canada upped their price objective on Exelixis from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $27.00 price objective on shares of Exelixis in a research note on Wednesday, April 10th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.29.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.